Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy.
Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, Italy.
Curr Oncol. 2024 Oct 10;31(10):6050-6060. doi: 10.3390/curroncol31100451.
High-risk acute myeloid leukemia has been associated with a poor outcome. Hematopoietic stem cell transplantation (HSCT) represents the only curative option for eligible patients. Relapse after HSCT is a dramatic event with poor chances of survival. With the aim of reducing the rate of post-HSCT relapse, maintenance treatment has been investigated in this setting. Results from clinical trials suggest an advantage in the use of a maintenance strategy; however, standardized guidelines are not yet available due to the lack of prospective clinical trials. In this review, we have reported the most important strategies adopted as post-HSCT maintenance, highlighting their efficacy, but the current research also opens questions.
高危急性髓系白血病的预后较差。造血干细胞移植（HSCT）是符合条件的患者唯一的治愈选择。HSCT 后复发是一个严重的事件，生存机会很差。为了降低 HSCT 后复发率，在这种情况下已经研究了维持治疗。临床试验的结果表明，维持治疗策略具有优势；然而，由于缺乏前瞻性临床试验，目前还没有标准化的指南。在这篇综述中，我们报告了作为 HSCT 后维持治疗采用的最重要的策略，强调了它们的疗效，但目前的研究也提出了一些问题。
